NexPoint Capital Inc. BDC Losses?

Soreide Law Group is examining potential investor claims involving recommendations of NexPoint Capital Inc. BDC, a publicly registered non-traded business development company sponsored by NexPoint Advisors L.P., following continued declines in the investment’s net asset value (“NAV”), limited liquidity opportunities, and ongoing concerns about investor losses.

NexPoint Capital Inc. BDC was marketed as an income-focused alternative investment with significant exposure to healthcare-related assets, including senior housing and medical facilities. Investors should be aware of recent developments involving falling share values, continued distributions despite declining NAV, and concerns surrounding the risks of non-traded BDC investments. The information below summarizes important facts investors should know.

About NexPoint

NexPoint Capital Inc. BDC is a non-traded business development company that invests primarily in private debt and alternative investments with a concentration in healthcare-related sectors. The investment has focused on senior housing, long-term care properties, and medical facilities intended to benefit from demographic trends tied to an aging population. Because the BDC is non-traded, investors generally do not have access to a public exchange to readily sell shares. The company also offers a dividend reinvestment plan (“DRIP”), which permits shareholders to reinvest distributions into additional shares priced in relation to the company’s NAV.

Concerns About NexPoint Capital Inc. BDC

Recent reports show that NexPoint Capital Inc. BDC’s NAV declined from $4.60 per share at year-end 2025 to $4.30 per share as of March 31, 2026. Earlier reports also reflected a longer-term decline from approximately $6.13 per share in 2020. At the same time, the company maintained a $0.09 per share distribution payable in April 2026 despite continued decreases in NAV. Reports noted concerns that ongoing distributions during periods of declining NAV may, in some cases, involve a return of investor capital rather than investment income.

The company also launched a tender offer in February 2026 to repurchase only up to 1% of outstanding shares at approximately $4.43 per share, leaving many investors with limited liquidity options. Additional concerns include concentration in healthcare-related investments, sector-specific risks, valuation uncertainty, and the illiquid nature of non-traded BDCs. Reports further stated that DRIP shares are currently being issued at the declining $4.30 NAV price.

Potential Sales Practice Violations

Brokers and financial advisors recommending NexPoint Capital Inc. BDC may have had obligations to fully explain the risks associated with declining NAV, limited liquidity, healthcare-sector concentration, and the speculative nature of non-traded BDCs.

Potential investor claims could involve recommendations that were unsuitable for conservative or income-oriented investors, failure to disclose that shares purchased at substantially higher prices had materially declined in value, misrepresentations regarding income stability or liquidity, overconcentration in illiquid alternative investments, or inadequate due diligence concerning the product’s structure and risks. Investors who suffered losses may be able to pursue recovery through FINRA arbitration or other legal remedies.

Did You Sustain Losses By Investing In NexPoint Capital Inc. BDC?

Did you suffer any losses because of investing in NexPoint Capital Inc. BDC because of your financial advisor or securities broker? You can contact Soreide Law Group at (888) 760-6552 or online and consult with a securities attorney regarding a potential recovery of your investment losses. Soreide Law Group has recovered losses for hundreds of individuals throughout the country. Also, our securities lawyers work on a contingency fee basis and advance all costs.